1. Home /
    2. Altai Protocol Library /
  2. New protocol: SubQ daratumumab + pomalidomide + dexamethasone for relapsed/refractory multiple myeloma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New protocol: SubQ daratumumab + pomalidomide + dexamethasone for relapsed/refractory multiple myeloma

New protocol: SubQ daratumumab + pomalidomide + dexamethasone for relapsed/refractory multiple myeloma
Study:
  • Open-label phase 3 trial. Relapsed/refractory MM patients who received >=1 prior line of therapy
  • Daratumumab subQ (1800 mg q1-2 wk) + Pomalidomide + dexamethasone (n=151) vs. Pd alone (n=153)
Efficacy:
  • >=VGPR: 51.0% vs. 19.6%
  • >=CR: 24.5% vs. 3.9%
  • Median PFS: 12.4 mos vs. 6.9 mos. HR for PFS = 0.63 [0.47 – 0.85]
Safety:
  • Grade >=3 adverse events: Neutropenia (68% vs. 51%), lymphopenia (12% vs. 3%), febrile neutropenia (9% vs. 3%), pneumonia (13% vs. 7%)

Presented at: 2021 ASH Annual Meeting; December 4, 2020. Abstract 412.

Dimopoulos MA, et al. Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM).

https://ash.confex.com/ash/2020/webprogram/Paper135874.html

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More